The aberrant activation of those EGFR signaling pathways, due to factors like cell-surface overexpression, autocrine activation, and mutations in the EGFR gene, is observed in various cancers, including lung, head and neck, cervical, colorectal, and brain cancers [11]. This evidence concerns the gene EGFR and brain cancer.